This trial is testing if a combination of two drugs can help control CLL/SLL that has been previously treated.
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
1 Primary · 0 Secondary · Reporting Duration: Up to completion of cycle 24 (each cycle is 28 days)
Side Effects for
1 Treatment Group
1 of 1
44 Total Participants · 1 Treatment Group
Primary Treatment: Pirtobrutinib · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is this research project still open to new participants?
"From what is detailed on clinicaltrials.gov, this particular trial has closed recruitment. The study was first announced on September 30th, 2022 and underwent its last edit on April 7th, 2022. Even though this opportunity to participate has passed, there are 2,954 other trials that are still recruiting patients." - Anonymous Online Contributor
Is it possible to experience negative side effects from Pirtobrutinib?
"Pirtobrutinib falls into the category of a phase 2 drug, meaning that while there is some data supporting its safety, there is no evidence yet to suggest that it is effective. Therefore, our team at Power gave it a score of 2." - Anonymous Online Contributor